Visual Atlas · Science

The 5-HT2A receptor

One receptor explains most of what psilocybin does. Understand 5-HT2A agonism and you understand why LSD feels related, why SSRIs blunt the effect, and why ketamine sits in a different category.

90-second quick read · deeper research available

Need the deeper research library?

This is the 90-second cliff-note read on imicrodosing.net. For cited research context, terminology, and broader education, use the full .org research library.

Read the full 5-HT2A research →Browse related 90-second reads →

5-HT2APrimary target

CortexWhere it concentrates

NMDAKetamine's route

In brief

Psilocin — the active form of psilocybin — is an agonist at the 5-HT2A serotonin receptor, concentrated in the cortex. Activating it drives the plasticity cascade and the perceptual effects. The classic psychedelics (psilocybin, LSD, DMT, mescaline) all share 5-HT2A agonism, which is why they share a family resemblance.

The mechanism explains the interactions. SSRIs can downregulate 5-HT2A over time and blunt psychedelic effects. Ketamine is not a 5-HT2A drug at all — it works through NMDA receptor antagonism, which is why it feels and behaves differently. When you understand the receptor, you understand the drug.

Visual walkthrough

Cover slide introducing the 5-HT2A receptor as a central target of classic psychedelics.

Meet the receptor: 5-HT2A is a serotonin receptor subtype and the primary target of classic psychedelics.

Where it concentrates: 5-HT2A is densely expressed in the cortex, especially in layer-5 pyramidal neurons.

Its normal job: 5-HT2A signalling modulates cognition, perception, and mood under serotonin.

Binding: psilocin acts as an agonist at 5-HT2A, activating the receptor in this context.

Why LSD feels familiar: LSD is also a 5-HT2A agonist, so classic psychedelics share a family resemblance.

Slide discussing reports and studies in which antidepressant use altered psilocybin effects; individual results vary.

Why ketamine is different: ketamine works through NMDA receptor antagonism, not 5-HT2A, so it sits in a separate class.

Slide summarizing 5-HT2A receptor involvement while noting that response and interactions are more complex than one mechanism.

Closing slide about the importance—and limits—of receptor-level explanations.

1 / 10

Swipe or tap the arrows to move through 10 slides

One receptor, and everything that follows from it

The target

Psilocin is a 5-HT2A serotonin receptor agonist. The receptor is densely expressed in the cortex, including on layer-5 pyramidal neurons that shape cortical output.

Why the family resembles itself

Psilocybin, LSD, DMT and mescaline all act at 5-HT2A. Shared agonism is why the classic psychedelics share a recognisable family of effects despite different chemistry.

The plasticity link

5-HT2A activation triggers the TrkB and mTOR signalling that drives dendritic spine growth — the receptor connects the perceptual effect to the structural one.

The SSRI interaction

Observational reports suggest SSRIs and SNRIs may weaken psilocybin effects for some people, while controlled escitalopram pretreatment did not produce a simple uniform reduction. The interaction cannot be predicted from receptor theory alone.

Ketamine is not in this club

Ketamine produces rapid plasticity too, but through NMDA receptor antagonism — a different pathway. It is grouped with psychedelics by outcome, not by receptor.

Antagonism confirms causation

Human ketanserin studies show that 5-HT2A blockade can reduce major acute psilocybin effects. Downstream structural and behavioral mechanisms are more complex and depend on the model studied.

What the data shows — and how strong it is

Strong Clinical + mechanisticModerate Survey + trackingEarly Promising, developingAnecdotal Widely reported only

Strong

Strong — receptor pharmacology5-HT2A agonism is well-established as central to the acute effects of classic psychedelics. It does not, by itself, settle every downstream mechanism or clinical outcome.

Moderate

Moderate — SSRI bluntingSurvey data report weaker-than-expected effects more often with SSRIs and SNRIs, but controlled findings are mixed and individual magnitude is uncertain.

Anecdotal

Anecdotal — individual receptor variationGenetic variation in 5-HT2A expression is proposed to explain individual differences in response — plausible and partly studied, but not a reliable individual predictor.

Verdict

5-HT2A signaling is central to classic psychedelic effects, but one receptor does not explain every response, interaction, or long-term outcome.

Common questions

Answered directly

Q · 01

What is the 5-HT2A receptor and why does it matter for psilocybin?

5-HT2A is a serotonin receptor subtype, densely expressed in the cortex. Psilocin, the active form of psilocybin, is a 5-HT2A agonist. Activating this receptor produces the perceptual effects and triggers the plasticity cascade, which is why it is the central mechanism of classic psychedelics.

Q · 02

Do SSRIs always blunt psilocybin effects?

Not always. Survey data report attenuation for many users, but a controlled escitalopram study did not show a simple uniform reduction. Medication, duration, dose, and individual biology may all matter; do not change treatment without a prescriber.

Q · 03

What is the difference between 5-HT2A agonism and NMDA antagonism?

Classic psychedelics such as psilocybin and LSD work by activating the 5-HT2A serotonin receptor. Ketamine works by blocking the NMDA glutamate receptor. Both can produce rapid neuroplasticity, but through different pathways, which is why ketamine is grouped with psychedelics by outcome rather than by receptor.

Product-format context

For product-format context, see the iMicrodosing.com products and client support.

View products & support →

← PreviousDefault mode network Next →Psychoplastogens